T. Rowe Price Associates’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $307M | Sell |
10,808,727
-529,371
| -5% | -$15M | 0.03% | 346 |
|
|
2025
Q1 | $335M | Buy |
11,338,098
+295,275
| +3% | +$8.72M | 0.04% | 325 |
|
|
2024
Q4 | $321M | Buy |
11,042,823
+408,861
| +4% | +$11.9M | 0.04% | 340 |
|
|
2024
Q3 | $488M | Sell |
10,633,962
-282,664
| -3% | -$13M | 0.06% | 281 |
|
|
2024
Q2 | $446M | Buy |
10,916,626
+3,487,519
| +47% | +$142M | 0.05% | 292 |
|
|
2024
Q1 | $190M | Buy |
7,429,107
+516,446
| +7% | +$13.2M | 0.02% | 427 |
|
|
2023
Q4 | $62.6M | Buy |
6,912,661
+296,238
| +4% | +$2.68M | 0.01% | 638 |
|
|
2023
Q3 | $42.2M | Sell |
6,616,423
-67,818
| -1% | -$433K | 0.01% | 737 |
|
|
2023
Q2 | $74.1M | Sell |
6,684,241
-180,144
| -3% | -$2M | 0.01% | 592 |
|
|
2023
Q1 | $105M | Buy |
6,864,385
+157,098
| +2% | +$2.41M | 0.02% | 501 |
|
|
2022
Q4 | $149M | Buy |
6,707,287
+1,538,264
| +30% | +$34.1M | 0.02% | 430 |
|
|
2022
Q3 | $84.4M | Sell |
5,169,023
-2,714,102
| -34% | -$44.3M | 0.01% | 517 |
|
|
2022
Q2 | $115M | Sell |
7,883,125
-102,410
| -1% | -$1.49M | 0.01% | 623 |
|
|
2022
Q1 | $147M | Buy |
7,985,535
+253,689
| +3% | +$4.69M | 0.01% | 621 |
|
|
2021
Q4 | $184M | Buy |
7,731,846
+641,196
| +9% | +$15.2M | 0.02% | 580 |
|
|
2021
Q3 | $175M | Buy |
7,090,650
+4,553,579
| +179% | +$112M | 0.02% | 583 |
|
|
2021
Q2 | $62.7M | Buy |
2,537,071
+779,336
| +44% | +$19.3M | 0.01% | 952 |
|
|
2021
Q1 | $38.3M | Buy |
1,757,735
+812,897
| +86% | +$17.7M | ﹤0.01% | 1095 |
|
|
2020
Q4 | $24.1M | Sell |
944,838
-12,813
| -1% | -$327K | ﹤0.01% | 1174 |
|
|
2020
Q3 | $27M | Buy |
957,651
+7,251
| +0.8% | +$204K | ﹤0.01% | 1071 |
|
|
2020
Q2 | $26.9M | Buy |
+950,400
| New | +$26.9M | ﹤0.01% | 1049 |
|